Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.

about

Skipping Multiple Exons to Treat DMD-Promises and Challenges.Shorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMD

P2860

Q52429827-B9A95390-B5B7-4625-8C3D-A5E021FE032C Q58577259-A78DE9CB-8B73-46D8-9011-E9F999238B45

P2860

Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.

Item

http://www.wikidata.org/entity/Q42378896

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Myoblasts and macrophages are ...... delivery to dystrophic muscle.

@en

Myoblasts and macrophages are ...... delivery to dystrophic muscle.

@nl

type

Item

label

Myoblasts and macrophages are ...... delivery to dystrophic muscle.

@en

Myoblasts and macrophages are ...... delivery to dystrophic muscle.

@nl

prefLabel

Myoblasts and macrophages are ...... delivery to dystrophic muscle.

@en

Myoblasts and macrophages are ...... delivery to dystrophic muscle.

@nl

P1476

Myoblasts and macrophages are ...... delivery to dystrophic muscle.

@en

P2093

Aiping Zhang

http://www.w3.org/2001/XMLSchema#string

Eric P Hoffman

http://www.w3.org/2001/XMLSchema#string

Jessica F Boehler

http://www.w3.org/2001/XMLSchema#string

Maria C Vila

http://www.w3.org/2001/XMLSchema#string

Marie Nearing

http://www.w3.org/2001/XMLSchema#string

Raul Heredia

http://www.w3.org/2001/XMLSchema#string

Sebahattin Cirak

http://www.w3.org/2001/XMLSchema#string

Terence A Partridge

http://www.w3.org/2001/XMLSchema#string

Yetrib Hathout

http://www.w3.org/2001/XMLSchema#string

P2860

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

X chromosome-linked muscular dystrophy (mdx) in the mouse

To scale or not to scale: the principles of dose extrapolation

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

What Can We Learn From Clinical Trials of Exon Skipping for DMD?

Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles

Genetic background affects properties of satellite cells and mdx phenotypes.

Regulatory interactions between muscle and the immune system during muscle regeneration

Functional significance of macrophage-derived exosomes in inflammation and pain

P2888

s41467-017-00924-7

P304

941

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41467-017-00924-7

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092152746

http://www.w3.org/2001/XMLSchema#string

P698

29038471

http://www.w3.org/2001/XMLSchema#string

P921

myoblast

P932

5643396

http://www.w3.org/2001/XMLSchema#string

Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.

about

P2860

P2860

Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P921

P932